UPDATE: Cornelius makes Bristol-Myers more valuable
Elevating Jim Cornelius from interim to permanent CEO of Bristol-Myers Squibb Co. makes the drug giant more expensive for another company to buy, an analyst told Bloomberg. Michael Krensavage of Raymond James & Associates said this morning’s announcement won’t stop speculation that the New York company could be a takeover target. But Cornelius now is […]